Search: WFRF:(Eliasson M)
> (2010-2014) >
Exenatide treatment...
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
-
Bunck, M. C. (author)
-
- Eliasson, Björn, 1959 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Corner, A. (author)
-
show more...
-
Heine, R. J. (author)
-
Shaginian, R. M. (author)
-
Taskinen, M. R. (author)
-
Yki-Jarvinen, H. (author)
-
- Smith, Ulf, 1943 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Diamant, M. (author)
-
show less...
-
(creator_code:org_t)
- 2011-02-23
- 2011
- English.
-
In: Diabetes, obesity & metabolism. - : Wiley. - 1463-1326 .- 1462-8902. ; 13:4, s. 374-377
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Preclinical studies suggest that incretin-based therapies may be beneficial for the bone; however, clinical data are largely lacking. We assessed whether the differential effects of these therapies on body weight differed with respect to their effect on bone mineral density (BMD) and markers of calcium homeostasis in patients with type 2 diabetes (T2D). Sixty-nine metformin-treated patients with T2D were randomized to exenatide twice daily (n = 36) or insulin glargine once daily (n = 33). Total body BMD, measured by dual-energy X-ray absorptiometry, and serum markers of calcium homeostasis were assessed before and after 44-week treatment. Exenatide or insulin glargine treatment decreased body weight by 6%. Endpoint BMD was similar in both groups after 44-week therapy (LSmean +/- s.e.m. between-group difference -0.002 +/- 0.007 g/cm(2) ; p = 0.782). Fasting serum alkaline phosphatase, calcium and phosphate remained unaffected. Forty-four-week treatment with exenatide or insulin glargine had no adverse effects on bone density in patients with T2D, despite differential effects on body weight.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Keyword
- Absorptiometry
- Photon
- Body Weight/*drug effects
- Bone Density/*drug effects/physiology
- Diabetes Mellitus
- Type 2/*drug therapy/physiopathology/radionuclide
- imaging
- Female
- Humans
- Male
- Middle Aged
- Peptides/administration & dosage/*pharmacology
- Randomized Controlled Trials as Topic
- Venoms/administration & dosage/*pharmacology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Bunck, M. C.
-
Eliasson, Björn, ...
-
Corner, A.
-
Heine, R. J.
-
Shaginian, R. M.
-
Taskinen, M. R.
-
show more...
-
Yki-Jarvinen, H.
-
Smith, Ulf, 1943
-
Diamant, M.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Dermatology and ...
- Articles in the publication
-
Diabetes, obesit ...
- By the university
-
University of Gothenburg